Donepezil (Aricept)

An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.

Also Known As:

Networked: 2266 relevant articles (346 outcomes, 612 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gauthier, Serge: 15 articles (01/2015 - 12/2002)
2.	Mori, Etsuro: 13 articles (01/2020 - 04/2005)
3.	Meguro, Kenichi: 13 articles (12/2018 - 04/2008)
4.	Burns, Alistair: 13 articles (12/2017 - 03/2003)
5.	Cummings, Jeffrey L: 12 articles (01/2021 - 01/2006)
6.	Ikeda, Manabu: 11 articles (01/2020 - 12/2009)
7.	Nath, Chandishwar: 11 articles (01/2016 - 05/2007)
8.	Zhang, Richard: 11 articles (02/2011 - 01/2003)
9.	Yang, Yuan-Han: 10 articles (07/2022 - 09/2008)
10.	Richardson, Sharon: 10 articles (06/2011 - 12/2004)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2004 - "Despite a sense of limited efficacy of this drug class among prescribers, number needed-to-treat analyses suggest donepezil is highly effective at reducing the long-term adverse outcomes associated with Alzheimer's disease." 10/01/2000 - "There have been a number of randomised, placebo-controlled trials of donepezil in the treatment of mild-moderate Alzheimer's disease and these report significant benefits for a proportion of patients. " 03/01/2000 - "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease. " 08/20/2017 - "Objective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg·d)] and middle [750 mg/(kg·d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg·d)]).In addition,C57BL/6J wild mice were selected as normal group.The" 06/20/2017 - "Objective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In"
2.	Dementia (Dementias) 09/01/2016 - "Any derived benefit seems to be independent of dementia severity and donepezil is the most cost-effective for Alzheimer's dementia. " 01/01/2020 - "Therefore, although PTD-ChAT and donepezil were both effective in the treatment of aged dementia mice, their mechanisms were significantly different. " 06/19/2015 - "Among anti-dementia drugs, donepezil showed significantly greater protective effects than placebo regarding %TBV/y (SMD=-0.43, 95%CI=-0.74 to -0.12, P=.007, N=1, n=164) and %VV/y (SMD=-0.51, 95%CI=-0.73 to -0.29, P<.00001, N=2, n=338). " 06/01/2010 - "Thus, the early diagnosis of dementia and prompt initiation of donepezil treatment is indicated for a good outcome. " 01/01/2001 - "In patients with mild dementia (n = 5), the qEEG analysis showed a significant reduction of the mean absolute theta activity (p = 0.05) by donepezil, particularly in frontal and temporo-parietal areas. "
3.	Cognitive Dysfunction 04/01/2012 - "Donepezil was found to improve global cognition at 1 year, but the benefit did not persist at year 2. Subjects with mild cognitive impairment at baseline who received donepezil experienced higher depression recurrence than did those who took placebo (p = 0.03); this effect was not observed in cognitively intact subjects (p = 0.39). " 09/27/2022 - "A single-center, randomized, parallel design study to evaluate the efficacy of donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker: the COG-EYE study protocol for a phase II trial." 08/24/2004 - "Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial." 01/01/2004 - "Extending studies for longer periods would be desirable to establish the efficacy of donepezil in patients with advanced stages of cognitive impairment. " 05/01/2022 - "Our in vivo results showed that SST administration improved cognitive impairment, similar to donepezil treatment (as a positive control), in NORT and PAT. "
4.	Parkinson Disease (Parkinson's Disease) 10/21/2015 - "Donepezil Regulates 1-Methyl-4-phenylpyridinium-Induced Microglial Polarization in Parkinson's Disease." 03/01/2015 - "Using 5-[(11)C]-methoxy-donepezil positron emission tomography, we studied 12 patients with early-to-moderate Parkinson's disease (three female; age 64 ± 9 years) and 12 age-matched control subjects (three female; age 62 ± 8 years). " 09/01/2005 - "Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study." 07/01/2005 - "Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study." 03/01/2002 - "Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease."
5.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 08/01/2009 - "Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated." 03/01/2004 - "Donepezil minimally effective for patients with vascular dementia." 03/01/2010 - "To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). " 10/01/2003 - "Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial." 02/01/2006 - "P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia."

Related Drugs and Biologics

1.	Cholinesterase Inhibitors (Anticholinesterases)
2.	Rivastigmine (Exelon)
3.	Galantamine (Galanthamine)
4.	Memantine (Namenda)
5.	Donepezil (Aricept)
6.	Acetylcholinesterase
7.	Cholinergic Agents (Cholinergics)
8.	Tacrine (Cognex)
9.	Scopolamine (Hyoscine)
10.	Ginkgo biloba extract (Rokan)

Related Therapies and Procedures

1.	Therapeutics
2.	Activities of Daily Living (ADL)
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Palliative Care (Palliative Therapy)